BiotechTube

ASP546C

Phase 1/2Recruiting
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastric or Gastro-esophageal Adenocarcinoma

Conditions

Gastric or Gastro-esophageal Adenocarcinoma, Pancreatic Adenocarcinoma

Trial Timeline

Mar 31, 2026 → Jul 31, 2029

NCT ID
NCT07488676

About ASP546C

ASP546C is a phase 1/2 stage product being developed by Astellas Pharma for Gastric or Gastro-esophageal Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07488676. Target conditions include Gastric or Gastro-esophageal Adenocarcinoma, Pancreatic Adenocarcinoma.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT07488676Phase 1/2Recruiting

Competing Products

20 competing products in Gastric or Gastro-esophageal Adenocarcinoma

See all competitors
ProductCompanyStageHype Score
pemetrexed + cisplatinEli LillyPhase 1/2
41
InfigratinibLianBioPhase 2
44
InfigratinibLianBioPhase 2
44
Ramucirumab + MEDI4736Eli LillyPhase 1
33
RamucirumabEli LillyPhase 2
52
Trastuzumab + Capecitabine + CisplatinCelltrionPhase 2
52
Trastuzumab + Fluorouracil + Cisplatin + CapecitabineChugai PharmaceuticalPhase 3
77
Fluorouracil (5-FU) + Capecitabine + Durvalumab + Oxaliplatin + Trastuzumab + Trastuzumab deruxtecan + Cisplatin + Pembrolizumab + Volrustomig + RilvegostomigDaiichi SankyoPhase 2
52
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
77
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine CombinationDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + BevacizumabDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan (T-DXd)Daiichi SankyoPre-clinical
23
DS-8201aDaiichi SankyoPhase 1
33
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Irinotecan + NimotuzumabDaiichi SankyoPhase 3
77
Trastuzumab Deruxtecan + pembrolizumab + Trastuzumab + ChemotherapyDaiichi SankyoPhase 3
77
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLODaiichi SankyoPhase 1/2
41

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85